Cathepsin S: From Molecular Regulation to Therapeutic Targeting, New Horizons for Selective Inhibition

Cathepsin S (CatS) is a protease that, unlike most human cysteine cathepsins, remains active at neutral pH, enabling functions in both the endolysosomal compartment and the extracellular space. It primes antigen presentation, remodels the extracellular matrix, and cleaves cytokines and receptors, placing it at the heart of inflammation, autoimmunity, pain, and cancer when its expression or activity is dysregulated. Despite the setbacks of CatK inhibitors, which warn against complete protease shutdown, the approval of brensocatib (a CatC/DPP1 inhibitor) for bronchiectasis supports the feasibility of therapeutic targeting of CatS. This review dissects how CatS is regulated, maps its substrates and roles in disease, and updates the landscape of natural and synthetic inhibitors that bind inside or outside the active site of the enzyme. Finally, it discusses emerging strategies for selective modulation of CatS activity.

Authors

Institutions

Publication Details

Journal
Biomolecules
Published
2026-11-19
DOI
https://doi.org/10.3390/biom16111683
Primary Topic
Protease and Inhibitor Mechanisms
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Cathepsin S: From Molecular Regulation to Therapeutic Targeting, New Horizons for Selective Inhibition

Ahlame Saidi, Florian Veillard, Alexis David, Gilles Lalmanach et al.
Biomolecules
Protease and Inhibitor Mechanisms
article

Cathepsin S: From Molecular Regulation to Therapeutic Targeting, New Horizons for Selective Inhibition

Ahlame Saidi, Florian Veillard, Alexis David, Gilles Lalmanach, Fabien Lecaille, Clarisse Brossier, Jasmine Imbert
article en

Abstract

Cathepsin S (CatS) is a protease that, unlike most human cysteine cathepsins, remains active at neutral pH, enabling functions in both the endolysosomal compartment and the extracellular space. It primes antigen presentation, remodels the extracellular matrix, and cleaves cytokines and receptors, placing it at the heart of inflammation, autoimmunity, pain, and cancer when its expression or activity is dysregulated. Despite the setbacks of CatK inhibitors, which warn against complete protease shutdown, the approval of brensocatib (a CatC/DPP1 inhibitor) for bronchiectasis supports the feasibility of therapeutic targeting of CatS. This review dissects how CatS is regulated, maps its substrates and roles in disease, and updates the landscape of natural and synthetic inhibitors that bind inside or outside the active site of the enzyme. Finally, it discusses emerging strategies for selective modulation of CatS activity.

BiomoleculesVol. 16(11)
Université de Tours (FR), Inserm (FR)
Protease and Inhibitor Mechanisms
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon